Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 23, 2025
Event: Entry into a new Credit Agreement and termination of the existing credit facility.
Key Financial Metrics and Capital Structure
This filing details a refinancing transaction rather than operational financial results. Key capital structure metrics include:
- New Term Loan: $580,000,000
- Delayed Draw Term Loan Commitments: $300,000,000
- Revolving Credit Facility: $100,000,000
- Total Facility Size: $980,000,000
- Interest Rate: SOFR plus a spread ranging from 2.75% to 3.75% based on the First Lien Net Leverage Ratio.
- Repayment Schedule: Quarterly installments commencing March 31, 2026.
Material Changes Versus Prior Period
The Company replaced its "Existing Credit Agreement" (dated July 28, 2024) with the new Credit Agreement on December 23, 2025. Material changes include:
- Debt Refinancing: The initial Term Loan proceeds were used to repay in full all outstanding obligations under the Existing Credit Agreement, including prepayment premiums and make-whole amounts.
- Liens Released: All liens and security interests securing the previous agreement were released.
- Covenant Structure: The new agreement introduces quarterly tested financial covenants, specifically a first lien secured net leverage ratio (allowing up to $250,000,000 of unrestricted cash to be netted) and a fixed charge coverage ratio.
Guidance, Outlook, and Risks
Management Commentary: The proceeds from the new facility, after repaying the existing debt and paying transaction fees, are designated for general corporate purposes. The Company retains the option to prepay loans at any time without premium or penalty.
Risks and Contingencies: The Company is subject to customary events of default and covenants. Failure to maintain the required leverage or coverage ratios could trigger a default. The filing notes that the description of the agreement is qualified by the full text to be filed in the 2025 Form 10-K.
Investor Verification Checklist
- Verify the exact amount of the prepayment premium and make-whole amount paid to terminate the July 2024 agreement.
- Review the full Credit Agreement (Exhibit to the 2025 10-K) for specific definitions of the First Lien Net Leverage Ratio and Fixed Charge Coverage Ratio.
- Confirm the current unrestricted cash and cash equivalents balance to assess the impact of the $250,000,000 netting allowance on the leverage covenant.
- Monitor the utilization of the $300,000,000 delayed draw term loan and $100,000,000 revolving facility.